This report was first published by Endpoints News. To see the original version, click here
Lawmakers on a bipartisan House panel conveyed they are ready to tackle China’s growing dominance in the development of new medicines and the ingredients that underpin the generic drug market.
During a Wednesday hearing of the House Select Committee on the Chinese Communist Party, witnesses including Strand Therapeutics CEO Jake Becraft and 8VC partner Francisco Gimenez described China’s growing share of the global clinical trial ecosystem. The core reason for the shift, they said, was that getting human data in the US takes too long and is too costly compared to China, where it is cheaper and quicker to accrue.
您已阅读17%（708字），剩余83%（3374字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。